Wellesley Pharmaceuticals Overview
- Founded
-
2011
- Status
-
Private
- Employees
-
1
- Latest Deal Type
-
Series D
- Latest Deal Amount
-
$10M
- Investors
-
3
Wellesley Pharmaceuticals General Information
Description
Developer of a pharmaceutical platform intended to treat nocturia disease of patients. The company's platform assists in treating the frequent need to urinate at night and to eliminate nocturia symptoms which can be disseminated, enabling patients to sleep well at night without using the bathroom.
Contact Information
Website
wellesleypharma.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
- 3 Valley View Drive
- Newtown, PA 18940
- United States
+1 (215) 000-0000
Wellesley Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series D) | 18-Apr-2016 | $10M | 000.00 | 0000 | Completed | Clinical Trials - Phase 2 |
| 3. Later Stage VC (Series C) | 01-Apr-2015 | 00.00 | 00.000 | 0000 | Completed | Clinical Trials - Phase 2 |
| 2. Angel (individual) | 01-Oct-2014 | $550K | $1.05M | 000.00 | Completed | Clinical Trials - Phase 2 |
| 1. Angel (individual) | 11-Jun-2014 | $500K | $500K | 000.00 | Completed | Clinical Trials - Phase 2 |
Wellesley Pharmaceuticals Patents
Wellesley Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20190374474-A1 | Pharmaceutical compositions and methods for weight loss | Abandoned | 11-Jun-2018 | 0000000000 | 0 |
| JP-2018538310-A | Composition for reducing the frequency of urination, and methods of making and using the same | Pending | 18-Dec-2015 | 000000000 | |
| AU-2016370313-A1 | Composition for reducing frequency of urination, method of making and use thereof | Abandoned | 18-Dec-2015 | 000000000 | |
| EP-3389661-A1 | Composition for reducing frequency of urination, method of making and use thereof | Withdrawn | 18-Dec-2015 | 000000000 | |
| EP-3389661-A4 | Composition for reducing frequency of urination, method of making and use thereof | Withdrawn | 18-Dec-2015 | A61K9/28 | 0 |
Wellesley Pharmaceuticals Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| David Dill | Founder, Chief Executive Officer, President and Chairman |
Wellesley Pharmaceuticals Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| David Dill | Wellesley Pharmaceuticals | Founder, Chief Executive Officer, President and Chairman | 000 0000 |
| John Balian | Self | Board Member | 000 0000 |
| Jukka Karjalainen MD | Self | Board Member | 000 0000 |
| Michael Myers Ph.D | Self | Board Member | 000 0000 |
Wellesley Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Wellesley Pharmaceuticals Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Cliff Miller | Angel (individual) | Minority | 000 0000 | 000000 0 | |
| Axella Bioventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Keiretsu Forum | Venture Capital | Minority | 000 0000 | 000000 0 |